Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/2/2025

Management of Intertriginous Candidiasis

Signs and Symptoms to Identify

  • Erythematous, moist, macerated skin in the inframammary fold with satellite pustules or papules at the periphery, often associated with pruritus and burning sensation, is a common presentation of intertriginous candidiasis in overweight or diabetic patients 1
  • Pruritus and burning sensation in the affected area, often worsening with heat and moisture, are characteristic symptoms of intertriginous candidiasis 1
  • White, curd-like discharge or scaling may be present on the skin surface, and foul odor can develop in chronic cases due to secondary bacterial colonization 1

Initial Management Approach

  • The Infectious Diseases Society of America recommends applying topical clotrimazole, miconazole, or nystatin cream twice daily to the affected area for 2-4 weeks, while keeping the inframammary area dry and avoiding occlusive clothing 1

Treatment of Moderate-to-Severe Disease

  • Oral fluconazole 100-200 mg daily for 7-14 days is appropriate for moderate-to-severe intertriginous candidiasis, particularly in diabetic patients, according to the Clinical Infectious Diseases guidelines 2, 3
  • For fluconazole-resistant C. glabrata, the Infectious Diseases Society of America recommends using amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days or oral flucytosine 25 mg/kg four times daily 2, 3

Escalation of Therapy

  • For fluconazole-refractory disease, the Clinical Infectious Diseases guidelines suggest using itraconazole solution 200 mg once daily or posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days 2, 3, 4
  • Alternative options include voriconazole 200 mg twice daily or amphotericin B deoxycholate oral suspension 100 mg/mL four times daily 2, 3, 4

Monitoring and Follow-Up

  • Clinical improvement should occur within 7-14 days of initiating appropriate therapy, and complete resolution is expected by 3-4 weeks after treatment completion, according to the Praxis Medical Insights guidelines 4
  • If symptoms persist beyond 14 days, fungal culture and susceptibility testing should be obtained to identify resistant species 4